bearish

Glenmark Pharma- Value Erosion Not Something New

620 Views31 May 2024 19:53
​Glenmark Pharmaceuticals FY24 results show 85% decrease in PBT due to exceptional items like sale gains and asset impairments. Regular impairments have been a recurring trend.
What is covered in the Full Insight:
  • Introduction
  • FY24 Results
  • Exceptional Items
  • Long-term Trends
  • Conclusion
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Rising
Nitin Mangal
Indian Accounting Research Analyst
Trudence Capital Advisors
IndiaEquitiesESGForensic Accounting
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x